-transparent.png){kind=logo}
Recently, a new therapy involving an extracorporal activation of orally administered 8-methoxypsoralen (8-MOP), photosensitizing furocoumarin, is established for the treatment of different skin diseases, extracorporeal photopheresis (ECP). The pharmacokinetic profile of 8-MOP has been pursued as part of a clinical study which should assess the efficacy of ECP in patients with progressive systemic sclerosis and cutaneous T-cell lymphoma. The enormous intra-individual variations proofed for plasma as well as buffy coat concentration are unfavourable for oral 8-MOP therapy. Therefore, the introduction of liquid 8-MOP formulation that allows the direct administration of the drug in to the treatment bag of the ECP device is challenging.
A Balogh, and
U Merkel, and
A Looks, and
R Vollandt, and
U Wollina
November 2009,
Transfusion,
A Balogh, and
U Merkel, and
A Looks, and
R Vollandt, and
U Wollina
April 1999,
Photodermatology, photoimmunology & photomedicine,
A Balogh, and
U Merkel, and
A Looks, and
R Vollandt, and
U Wollina
August 2020,
Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology,
A Balogh, and
U Merkel, and
A Looks, and
R Vollandt, and
U Wollina
February 2017,
Journal of clinical apheresis,
A Balogh, and
U Merkel, and
A Looks, and
R Vollandt, and
U Wollina
October 2021,
Transfusion,
A Balogh, and
U Merkel, and
A Looks, and
R Vollandt, and
U Wollina
January 2022,
Frontiers in oncology,
A Balogh, and
U Merkel, and
A Looks, and
R Vollandt, and
U Wollina
January 1986,
Current problems in dermatology,
A Balogh, and
U Merkel, and
A Looks, and
R Vollandt, and
U Wollina
November 2013,
Transfusion,
A Balogh, and
U Merkel, and
A Looks, and
R Vollandt, and
U Wollina
April 1993,
Journal of the American Academy of Dermatology,
A Balogh, and
U Merkel, and
A Looks, and
R Vollandt, and
U Wollina
January 1989,
The Journal of investigative dermatology,
